Your Shopping Cart Is Empty
Continue Shopping
Latest Publications Upcoming Publications Company Profiles IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases.
1.1 Company Overview
1.2 Company Snapshot
1.3 Operating Business Segment
1.4 Business Performance
1.5 Key Strategic moves and Development
TABLE 1.. GRIFOLS S.A SNAPSHOT
TABLE 2. GRIFOLS S.A OPERATING SEGEMENTS
FIGURE 1. GRIFOLS S.A:REVENUE, 2013-2015, ($MILLION)
FIGURE 2. FINANCIAL OF GRIFOLS S.A, BY GEOGRAPHY, (2015)
FIGURE 3. FINANCIAL GRIFOLS S.A., BY PRODUCT GROUPS, (2015)
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers
PDF Format 